ResearcherUniversity of FloridaActive in the last 2 years

Guangrong Zheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8106-6663; OpenAlex author ID A5058794772; NIH RePORTER profile ID 9208440. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 1
Labs led: 1
Collaborators: 12

Papers, trials and grants by year

2022: 1 paper · 2023: 1 grant · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 3

The Combination of a BCL-xL PROTAC and an mTOR Inhibitor Sensitizes Pancreatic Ductal Adenocarcinoma to KRAS G12D Inhibitor Treatment. Co-author DOI 10.3390/cancers18060920 ↗
A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR. Co-author DOI 10.1016/j.neo.2024.101070 ↗
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216. Co-author DOI 10.1158/1535-7163.mct-21-0474 ↗

Grants 1

Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancer R01CA242003 ↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Daohong Zhou · 3 shared papers, 1 shared grant, 2022–2026 · strength 1.28
Jose Gilberto Trevino · 2 shared papers, 1 shared grant, 2022–2025 · strength 0.97
Sajid Ullah Khan · 2 shared papers, 2022–2026 · strength 0.42
- Paper The Combination of a BCL-xL PROTAC and an mTOR Inhibitor Sensitizes Pancreatic Ductal Adenocarcinoma to KRAS G12D Inhib… DOI 10.3390/cancers18060920 ↗
- Paper Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216. DOI 10.1158/1535-7163.mct-21-0474 ↗
Javed Miyan · 1 shared paper, 2026 · strength 0.30
- Paper The Combination of a BCL-xL PROTAC and an mTOR Inhibitor Sensitizes Pancreatic Ductal Adenocarcinoma to KRAS G12D Inhib… DOI 10.3390/cancers18060920 ↗
Vignesh Vudatha · 1 shared paper, 2026 · strength 0.30
- Paper The Combination of a BCL-xL PROTAC and an mTOR Inhibitor Sensitizes Pancreatic Ductal Adenocarcinoma to KRAS G12D Inhib… DOI 10.3390/cancers18060920 ↗
Song Han · 1 shared paper, 2025 · strength 0.24
- Paper A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR. DOI 10.1016/j.neo.2024.101070 ↗
Gerik W. Tushoski-Alemán · 1 shared paper, 2025 · strength 0.24
- Paper A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR. DOI 10.1016/j.neo.2024.101070 ↗
Steven J. Hughes · 1 shared paper, 2025 · strength 0.24
- Paper A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR. DOI 10.1016/j.neo.2024.101070 ↗
Thomas J. George · 1 shared paper, 2025 · strength 0.24
- Paper A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR. DOI 10.1016/j.neo.2024.101070 ↗
Dinesh Thummuri · 1 shared paper, 2022 · strength 0.12
- Paper Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216. DOI 10.1158/1535-7163.mct-21-0474 ↗
Patrick W. Underwood · 1 shared paper, 2022 · strength 0.12
- Paper Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216. DOI 10.1158/1535-7163.mct-21-0474 ↗
Andrea N. Riner · 1 shared paper, 2022 · strength 0.12
- Paper Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216. DOI 10.1158/1535-7163.mct-21-0474 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.